GSK receives approval from FDA for Jemperli
Jemperli has been designed to attach to the PD-1 receptor and blocks its interaction with the PD-L1 and PD-L2 ligands. The antibody received accelerated approval in April 2021
AB-101 is a non-genetically modified, cord blood-derived, allogeneic, cryopreserved, ADCC-enhancing NK cell therapy candidate for use along with monoclonal antibodies or innate-cell engagers in the out-patient environment. Artiva